• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物整体生理基于药代动力学(WB-PBPK)建模的评估。

Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.

机构信息

Department of Biosciences, Faculty of Health and Life Sciences, Capital University of Science and Technology, Islamabad, Pakistan.

Department of Biosciences, Faculty of Health and Life Sciences, Capital University of Science and Technology, Islamabad, Pakistan.

出版信息

J Theor Biol. 2018 Aug 14;451:1-9. doi: 10.1016/j.jtbi.2018.04.032. Epub 2018 Apr 26.

DOI:10.1016/j.jtbi.2018.04.032
PMID:29704489
Abstract

The Physiologically based pharmacokinetic (PBPK) modeling is a supporting tool in drug discovery and improvement. Simulations produced by these models help to save time and aids in examining the effects of different variables on the pharmacokinetics of drugs. For this purpose, Sheila and Peters suggested a PBPK model capable of performing simulations to study a given drug absorption. There is a need to extend this model to the whole body entailing all another process like distribution, metabolism, and elimination, besides absorption. The aim of this scientific study is to hypothesize a WB-PBPK model through integrating absorption, distribution, metabolism, and elimination processes with the existing PBPK model.Absorption, distribution, metabolism, and elimination models are designed, integrated with PBPK model and validated. For validation purposes, clinical records of few drugs are collected from the literature. The developed WB-PBPK model is affirmed by comparing the simulations produced by the model against the searched clinical data. . It is proposed that the WB-PBPK model may be used in pharmaceutical industries to create of the pharmacokinetic profiles of drug candidates for better outcomes, as it is advance PBPK model and creates comprehensive PK profiles for drug ADME in concentration-time plots.

摘要

生理药代动力学(PBPK)模型是药物发现和改进的辅助工具。这些模型产生的模拟有助于节省时间,并有助于检查不同变量对药物药代动力学的影响。为此,Sheila 和 Peters 提出了一种能够进行模拟以研究特定药物吸收的 PBPK 模型。需要将该模型扩展到全身,除了吸收之外,还包括分布、代谢和消除等所有其他过程。这项科学研究的目的是通过将吸收、分布、代谢和消除过程与现有的 PBPK 模型相结合,假设一个 WB-PBPK 模型。设计、整合吸收、分布、代谢和消除模型,并对其进行验证。为了验证目的,从文献中收集了一些药物的临床记录。通过将模型产生的模拟与搜索到的临床数据进行比较,对开发的 WB-PBPK 模型进行了验证。提出 WB-PBPK 模型可用于制药行业,为药物候选物创建药代动力学曲线,以获得更好的结果,因为它是一种先进的 PBPK 模型,可以在浓度-时间图中为药物 ADME 创建全面的 PK 曲线。

相似文献

1
Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.药物整体生理基于药代动力学(WB-PBPK)建模的评估。
J Theor Biol. 2018 Aug 14;451:1-9. doi: 10.1016/j.jtbi.2018.04.032. Epub 2018 Apr 26.
2
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.制药研究和制造商协会(PHRMA)与美国疾病控制与预防中心(CPCDC)关于人体药代动力学预测模型的倡议,第5部分:使用基于生理学的药代动力学建模方法预测人体血浆浓度-时间曲线
J Pharm Sci. 2011 Oct;100(10):4127-57. doi: 10.1002/jps.22550. Epub 2011 May 3.
3
Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.通过基于生理的药代动力学模拟血浆浓度-时间曲线来识别药物的肠道损失。
Clin Pharmacokinet. 2008;47(4):245-59. doi: 10.2165/00003088-200847040-00003.
4
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.体内研究前的药代动力学预测。II. 药物处置的通用生理药代动力学模型
J Pharm Sci. 2002 May;91(5):1358-70. doi: 10.1002/jps.10128.
5
Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.用于生理药代动力学(PBPK)模型评估的结构和功能药代动力学类似物。
Regul Toxicol Pharmacol. 2018 Nov;99:61-77. doi: 10.1016/j.yrtph.2018.09.008. Epub 2018 Sep 8.
6
Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.基于生理学的全身药代动力学模型:其在临床药物开发中的应用。
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1143-52. doi: 10.1517/17425255.4.9.1143.
7
Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.基于生理的药代动力学建模工具的开发与应用以支持药物发现。
Chem Biodivers. 2005 Nov;2(11):1462-86. doi: 10.1002/cbdv.200590119.
8
Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.通过改进生理基于药代动力学方法的计算过程成功预测人体药代动力学。
J Pharm Sci. 2019 Aug;108(8):2718-2727. doi: 10.1016/j.xphs.2019.03.002. Epub 2019 Mar 12.
9
Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.用于线形分析的通用生理药代动力学模型评估。
Clin Pharmacokinet. 2008;47(4):261-75. doi: 10.2165/00003088-200847040-00004.
10
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.基于生理学的药物纳米颗粒药代动力学(PBPK)建模
AAPS J. 2017 Jan;19(1):26-42. doi: 10.1208/s12248-016-0010-3. Epub 2016 Nov 10.

引用本文的文献

1
Formulation Strategy of BCS-II Drugs by Coupling Mechanistic In-Vitro and Nonclinical In-Vivo Data with PBPK: Fundamentals of Absorption-Dissolution to Parameterization of Modelling and Simulation.通过将体外机制性数据和非临床体内数据与生理药代动力学(PBPK)相结合来制定BCS-II类药物的策略:从吸收-溶出基础到建模与模拟的参数化
AAPS PharmSciTech. 2025 Apr 17;26(5):106. doi: 10.1208/s12249-025-03093-9.